Biomarkers of mineralocorticoid receptor activation

Patent metadata

Field	Value
Publication number	US-10041122-B2
Application number	US-201615188198-A
Country	US
Kind code	B2
Filing date	Jun 21, 2016
Priority date	Oct 24, 2008
Publication date	Aug 7, 2018
Grant date	Aug 7, 2018

Abstract

The present invention relates to the use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and/or SERPINA3 as biomarkers of the Mineralocorticoid Receptor (MR) activation in a patient. More particularly, the present invention relates to a method for predicting the responsiveness of a patient to a treatment with a MR antagonist or an aldosterone synthase inhibitor, said method comprising determining in a biological sample obtained from said patient the expression level of the NGAL gene and/or of the SERPINA3 gene.

First claim

The invention claimed is:

1. A method for treating a patient affected with a cardiovascular disease, diabetes, obesity or metabolic syndrome, comprising the steps of
measuring in a biological sample obtained from said patient an expression level of one or two biomarkers selected from the group consisting of the Neutrophil Gelatinase-Associated Lipocalin (NGAL) gene and the SERPINA3 gene;
comparing said expression level to a reference value determined from corresponding biomarker expression levels obtained from a population of subjects not affected with a cardiovascular disease, diabetes, obesity or metabolic syndrome; and
administering to said patient a mineralocorticoid receptor (MR) antagonist or an aldosterone synthase inhibitor if said expression level is higher than the reference value.

2. The method of claim 1 , wherein said cardiovascular disease is congestive heart failure or hypertension.

Assignees

• Inst Nat Sante Rech Med

Inventors

• Jaisser Frederic
• Farman Nicolette
• Sainte-Marie Yannis
• Latouche Celine
• Steenman Marja

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title